These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 17541390)

  • 1. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
    Strasser RH; Puig JG; Farsang C; Croket M; Li J; van Ingen H
    J Hum Hypertens; 2007 Oct; 21(10):780-7. PubMed ID: 17541390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
    Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
    Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
    J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
    Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Smith B; Weissbach N; Maboudian M; Botha J; van Ingen H
    Circulation; 2009 Jan; 119(3):417-25. PubMed ID: 19139391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
    Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A
    Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
    Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Bush C; Keefe DL
    J Hypertens; 2009 Jul; 27(7):1493-501. PubMed ID: 19444142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
    Pool JL; Glazer R; Weinberger M; Alvarado R; Huang J; Graff A
    Clin Ther; 2007 Jan; 29(1):61-73. PubMed ID: 17379047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
    Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction.
    Ito S; Nakura N; Le Breton S; Keefe D
    Hypertens Res; 2010 Jan; 33(1):62-6. PubMed ID: 19927154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.
    Duprez DA; Munger MA; Botha J; Keefe DL; Charney AN
    J Hum Hypertens; 2010 Sep; 24(9):600-8. PubMed ID: 20033075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
    Yarows SA; Oparil S; Patel S; Fang H; Zhang J
    Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.
    Zhu JR; Sun NL; Yang K; Hu J; Xu G; Hong H; Wang R; Tu YM; Ritter S; Keefe D;
    Hypertens Res; 2012 Jan; 35(1):28-33. PubMed ID: 21900941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
    Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.